IDH2 and chondrosarcoma: Target therapies with potential activity in chondrosarcoma include antiangiogenic agents, mTOR inhibitors, hedgehog inhibitors, histone deacetylase inhibitors, immunotherapy, and, more recently, IDH inhibitors.